RT Journal Article
SR Electronic
T1 Heterologous prime-boost immunization with CoronaVac and Convidecia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.03.21263062
DO 10.1101/2021.09.03.21263062
A1 Li, Jingxin
A1 Hou, Lihua
A1 Guo, Xiling
A1 Jin, Pengfei
A1 Wu, Shipo
A1 Zhu, Jiahong
A1 Pan, Hongxing
A1 Wang, Xue
A1 Song, Zhizhou
A1 Wan, Jingxuan
A1 Cui, Lunbiao
A1 Li, Junqiang
A1 Wang, Xuewen
A1 Jin, Lairun
A1 Liu, Jingxian
A1 Shi, Fengjuan
A1 Xu, Xiaoyu
A1 Chen, Yin
A1 Zhu, Tao
A1 Chen, Wei
A1 Zhu, Fengcai
YR 2021
UL http://medrxiv.org/content/early/2021/09/06/2021.09.03.21263062.abstract
AB Background The safety and immunogenicity of heterologous prime-boost COVID-19 vaccine regimens with one shot of a recombinant adenovirus type-5-vectored COVID-19 vaccine Convidecia has not been reported.Methods We conducted a randomized, controlled, observer-blinded trial of heterologous prime-boost immunization with CoronaVac and Convidecia in healthy adults 18-59 years of age. Eligible participants who were primed with one or two doses of CoronaVac were randomly assigned at a 1:1 ratio to receive a booster dose of Convidecia or CoronaVac. Participants were masked to the vaccine received but not to the three-dose or two-dose regimen. The occurrences of adverse reactions within 28 days after the vaccination were documented. The geometric mean titers of neutralizing antibodies against live SARS-CoV-2 virus were measured at 14 and 28 days after the booster vaccination.Results Between May 25 and 26, 2021, a total of 300 participants were enrolled. Participants who received a booster shot with a heterologous dose of Convidecia reported increased frequencies of solicited injection-site reactions than did those received a homogeneous dose of CoronaVac, but frequencies of systemic reactions. The adverse reactions were generally mild to moderate. The heterologous immunization with Convidecia induced higher live viral neutralizing antibodies than did the homogeneous immunization with CoronaVac (197.4[167.7, 232.4] vs. 33.6[28.3, 39.8] and 54.4[37. 9, 78.0] vs. 12.8[9.3, 17.5]) at day 14 in the three- and two-dose regimen cohort, respectively.Conclusions The heterologous prime-boost regimen with Convidecia after the priming with CoronaVac was safe and significantly immunogenic than a homogeneous boost with CoronaVac (ClinicalTrials.gov, number NCT04892459).Competing Interest StatementXue Wang, Jingxuan Wan, Junqiang Li, Tao Zhu are employees of CanSino Biologics. All other authors declare no competing interests.Clinical TrialNCT04892459Funding StatementNational Natural Science Foundation of ChinaAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial protocol was reviewed and approved by the institutional review board of the Jiangsu Provincial Center of Disease Control and Prevention.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe results supporting the findings in this study are available upon request from the corresponding authors.